U.S. Patent 10,519,139: Selinexor Form A Claims, Exclusivity, Litigation and Generic Risk
U.S. Patent No. 10,519,139 protects a specific crystalline form of selinexor, the active ingredient in Xpovio, combined with defined particle-size characteristics. The patent does not claim every selinexor composition. Its core limitation is a composition containing selinexor Form A with a unimodal particle-size distribution and a d(0.9) value of 100 microns or less. Narrower claims specify diffraction peaks, thermal behavior, particle-size ranges, and cancer or wound-healing uses.
The patent was assigned to Karyopharm Therapeutics Inc. and issued on December 31, 2019. Its nominal patent term extends into 2035, subject to any applicable patent-term adjustment or extension recorded by the USPTO.[1]
What drug and technology does U.S. Patent 10,519,139 cover?
The claimed compound is selinexor, also known as KPT-330, an orally active selective inhibitor of nuclear export. Selinexor inhibits exportin 1, also called CRM1 or XPO1. Xpovio is the marketed product.
The patent focuses on solid-state and particle-engineering characteristics rather than the basic discovery of CRM1 inhibition. It covers:
- Selinexor Form A.
- Specified X-ray powder diffraction peaks.
- A differential scanning calorimetry endotherm at approximately 179°C.
- Unimodal particle-size distributions.
- d(0.9), d(0.5), and d(0.1) limits.
- Pharmaceutical compositions containing the solid form.
- Treatment of CRM1-associated disorders.
- Treatment of specified cancers.
- Wound-healing methods.
The practical value of the patent is its potential coverage of the commercial drug substance used to manufacture Xpovio tablets. A generic developer could avoid infringement only if its selinexor material does not satisfy the claimed solid-form and particle-size limitations, or if another valid noninfringement or invalidity position applies.
What are the independent claims in Patent 10,519,139?
Claims 1, 15, 17, 22 and 28 are the principal independent claims.
| Claim |
Claim category |
Principal limitations |
| 1 |
Composition |
Selinexor Form A, at least three specified XRPD peaks, and unimodal d(0.9) of 100 microns or less |
| 15 |
Treatment method |
Administering the pharmaceutical composition to treat a CRM1-associated disorder |
| 17 |
Treatment method |
Administering the pharmaceutical composition to promote wound healing |
| 22 |
Treatment method |
Administering the claimed Form A composition for a CRM1-associated disorder |
| 28 |
Treatment method |
Administering the claimed Form A composition to promote wound healing |
Claim 1 is the commercial center of gravity. It is a composition claim and does not require a particular disease, dosage, route or excipient. It does, however, require every material limitation:
- The compound must be Form A.
- The material must exhibit at least three of the listed XRPD peaks.
- The particle-size distribution must be unimodal.
- The d(0.9) must be 100 microns or less.
A material that meets the crystalline-form requirement but has a d(0.9) above 100 microns would fall outside claim 1 as written, assuming the particle-size result is reliable and representative of the accused product.
How do the dependent claims narrow the patent scope?
Claims 2 through 13 define progressively narrower solid-form and particle-size embodiments.
Crystalline-form limitations
Claims 3 through 6 increase the XRPD specificity:
- Claim 3 identifies peaks at approximately 4.4°, 19.9°, 21.3° and 22.0° 2θ.
- Claim 4 adds peaks at approximately 20.3°, 23.5° and 25.0°.
- Claim 5 recites a broader fingerprint with additional peaks at approximately 13.1°, 15.8°, 18.2°, 23.7°, 27.0°, 28.3° and 28.5°.
- Claim 6 refers to an XRPD pattern substantially corresponding to Figure 1A.
Claim 7 adds a DSC endothermic peak at approximately 179°C. This limitation can assist infringement analysis, but a DSC peak alone would not establish infringement because claim 7 remains dependent on claim 1.
Particle-size limitations
| Claim |
Particle-size limitation |
| 2 |
d(0.9) of 70 microns or less |
| 8 |
d(0.9) from 10 to 100 microns |
| 9 |
d(0.9) from 10 to 70 microns |
| 10 |
d(0.5) from 10 to 35 microns |
| 11 |
d(0.1) from 5 to 15 microns |
| 12 |
d(0.9):d(0.1) ratio from 2 to 10 |
| 13 |
d(0.9):d(0.5) ratio from 1.5 to 4.5 |
The claims use standard cumulative particle-size terminology:
- d(0.1): 10% of particles are smaller than the stated size.
- d(0.5): median particle size.
- d(0.9): 90% of particles are smaller than the stated size.
The unimodal-distribution requirement is important. A generic manufacturer could face infringement risk even if its median particle size differs from the reference product, provided the material remains Form A and satisfies the applicable d(0.9) limitation.
What formulations are protected by Patent 10,519,139?
Claim 14 covers a pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier. The claim does not require a particular tablet excipient, coating, dose strength or release profile.
The patent therefore reaches a formulation containing the protected Form A particles when the underlying drug substance satisfies claim 1. It is not limited to tablets. Depending on claim construction and product composition, capsules, powders, suspensions and other oral dosage forms could create exposure if they contain the claimed crystalline material and particle distribution.
The patent does not expressly claim:
- A specific excipient combination.
- A specific tablet strength.
- A particular dissolution profile.
- A sustained-release formulation.
- A particular manufacturing process.
- A specific dosage regimen.
Those limitations may be covered by other patents or patent families relating to selinexor, Xpovio formulations, manufacturing and therapeutic use.
What method-of-use patents and therapeutic uses are covered?
Claims 15 through 28 cover methods involving CRM1-associated disorders. The listed disease classes include:
- Leukemia, lymphoma and myeloma.
- Multiple myeloma.
- Diffuse large B-cell lymphoma.
- Follicular and mantle-cell lymphoma.
- Acute and chronic leukemias.
- Lung, breast, ovarian, prostate and pancreatic cancers.
- Melanoma and glioblastoma.
- Myelodysplastic syndrome.
- Inflammatory and autoimmune disorders.
- Viral, ophthalmological, neurodegenerative and respiratory disorders.
- Wound healing.
Claims 18 through 21 narrow the cancer claims, with claims 20 and 26 specifically directed to multiple myeloma and claims 21 and 27 directed to diffuse large B-cell lymphoma.
The method claims require use of the claimed composition. They do not independently cover administration of any selinexor formulation. A product that uses a different solid form could avoid these claims, although other selinexor method patents may remain relevant.
What is the FDA and Orange Book status of Patent 10,519,139?
Xpovio is FDA-approved and contains selinexor. The FDA first approved Xpovio in 2019 for relapsed or refractory diffuse large B-cell lymphoma under the accelerated-approval pathway. The agency later approved additional multiple-myeloma use, including use with dexamethasone in heavily pretreated patients.[2]
U.S. Patent 10,519,139 is associated with the Xpovio patent estate and has been identified in public drug-patent and Orange Book records for selinexor products. Orange Book listing creates a statutory basis for an ANDA applicant to certify under Paragraph IV that the listed patent is invalid, unenforceable or will not be infringed.[3]
The Orange Book status should be evaluated together with all listed Xpovio patents. A generic applicant that defeats Patent 10,519,139 could still face other listed patents covering selinexor composition, use or formulation.
When does Patent 10,519,139 lose exclusivity?
The patent issued December 31, 2019. Public patent databases identify a nominal expiration in September 2035 based on the patent family’s priority and filing history, subject to USPTO-recorded patent-term adjustment.[1]
The relevant exclusivity dates are different:
| Exclusivity category |
Approximate status |
| Patent 10,519,139 |
Nominal term into September 2035 |
| FDA new chemical entity exclusivity |
Expired before the patent term |
| FDA orphan exclusivity |
Product- and indication-specific; separate from this patent |
| Patent-term extension |
Must be confirmed in the USPTO and Orange Book records |
| Generic entry |
May occur before patent expiration if a Paragraph IV challenge succeeds or a settlement permits entry |
Patent expiration does not automatically equal commercial generic entry. Litigation settlements, pediatric exclusivity, other listed patents, regulatory exclusivity and injunctions can alter the effective entry date.
How strong is the patent estate for selinexor Form A?
The estate is strongest against a generic that reproduces the commercial drug substance and manufacturing profile.
Strengths
- Claim 1 combines the active compound, crystalline form and particle-size distribution.
- Form A is identified by multiple independent analytical characteristics.
- Dependent claims provide alternative XRPD and particle-size positions.
- Claim 14 extends the composition protection into pharmaceutical formulations.
- Treatment claims create additional exposure for use in covered cancers.
- The claimed specifications appear directed to commercially relevant material rather than a purely laboratory polymorph.
Vulnerabilities
- Claim 1 requires a unimodal distribution, which may create an evidentiary dispute over measurement method and batch variability.
- Particle-size values can vary with milling, sieving, agglomeration and analytical protocol.
- The claim requires Form A plus defined XRPD characteristics, creating potential design-around options using another polymorph, amorphous material or a different particle profile.
- The broad treatment claims may face written-description, enablement or anticipation challenges depending on the prior art and the patent specification.
- Claims 15 and 22 overlap substantially, reducing practical distinction between the pharmaceutical-composition and composition-only method pathways.
The patent is more difficult to design around at the drug-substance level than at the formulation level. Changing an excipient may not avoid claim 1 if the same Form A particles are used.
Which companies are challenging selinexor patents?
No publicly established, FDA-approved generic selinexor competitor or final Paragraph IV judgment involving U.S. Patent 10,519,139 was identified in the cited public records. The absence of an identified public challenge does not establish that no confidential ANDA filing, patent certification or pre-litigation notice exists.
Karyopharm remains the principal U.S. commercial rights holder for Xpovio. Menarini has held commercial rights outside the United States under a global collaboration, while Antengene has held rights in Greater China under a separate transaction.[4][5]
What licensing deals affect the patent landscape?
Karyopharm’s licensing arrangements expand the commercial relevance of the patent family outside the United States.
In 2020, Karyopharm granted Antengene rights to develop and commercialize selinexor in Greater China. Public disclosures described upfront consideration, equity investment, milestone payments and royalties.[4]
Karyopharm later entered a commercialization agreement with Menarini for selinexor in markets outside the United States. The transaction included upfront and potential milestone payments, with royalties tied to commercial sales.[5]
These deals do not change U.S. patent ownership or the scope of Patent 10,519,139. They affect regional enforcement, sublicensing, manufacturing control and the economic value of the patent estate.
What generic launch scenarios exist for Xpovio?
Launch after patent litigation
An ANDA applicant could file a Paragraph IV certification and seek a judgment that Patent 10,519,139 is invalid, unenforceable or not infringed. A timely patent-infringement action could trigger the Hatch-Waxman 30-month stay, subject to statutory exceptions and FDA procedures.[3]
Launch after design-around
A generic could attempt to use:
- A different polymorph.
- An amorphous form.
- A particle-size distribution with d(0.9) above the claimed threshold.
- A multimodal distribution.
- A formulation that does not contain the claimed Form A material.
Each route would require analytical confirmation. A nominally different manufacturing process would not avoid infringement if it produces the claimed Form A particles.
Launch under settlement
Karyopharm could settle with a generic applicant and permit a defined future launch date. The settlement could also impose restrictions on formulation, indication, supply or manufacturing source.
How does Patent 10,519,139 compare with basic selinexor patents?
| Patent layer |
Typical subject matter |
Commercial effect |
| Core compound patents |
Selinexor and related CRM1 inhibitors |
Broadest chemical coverage, generally earlier expiration |
| Solid-form patents |
Form A and other crystalline or amorphous forms |
Controls drug-substance selection |
| Particle-engineering claims |
Milling and particle-size distributions |
Targets scalable commercial material |
| Formulation patents |
Tablets, excipients and dosage forms |
Limits product replication |
| Method-of-use patents |
Multiple myeloma, DLBCL and other disorders |
Supports indication-specific enforcement |
| Manufacturing patents |
Crystallization, isolation and processing |
Raises supply-chain and process-design barriers |
Patent 10,519,139 is a solid-form and particle-size patent with attached pharmaceutical-composition and use claims. It is narrower than a basic composition-of-matter patent but may be more directly relevant to an ANDA product designed to copy Xpovio.
Key Takeaways
- U.S. Patent 10,519,139 principally protects selinexor Form A with a unimodal d(0.9) particle size of 100 microns or less.
- Claims 2 through 13 add narrower XRPD, DSC and particle-size limitations.
- Claim 14 extends protection to pharmaceutical compositions containing the claimed particles.
- Claims 15 through 28 cover CRM1-associated disorders, cancer treatment and wound healing.
- The patent is relevant to Xpovio and its generic-entry risk.
- The nominal patent term extends into September 2035, subject to official USPTO adjustments.
- The most credible design-around strategies involve a different polymorph, an amorphous form or a particle-size distribution outside the claim limitations.
- A generic applicant could challenge the patent through Paragraph IV certification or seek a settlement-based launch.
- No publicly established final Paragraph IV judgment involving this patent was identified in the cited records.
- The patent should be analyzed with the full Orange Book and global selinexor patent estate, including core compound, formulation, use and manufacturing patents.
Frequently Asked Questions
Does Patent 10,519,139 cover all selinexor products?
No. It covers compositions containing the specified selinexor Form A and particle-size characteristics. Selinexor in another polymorphic or amorphous form may fall outside the claims.
What does d(0.9) mean in the patent claims?
d(0.9) is the particle diameter below which 90% of the measured particles fall. Claim 1 requires a value of 100 microns or less.
Can a generic avoid the patent by changing tablet excipients?
Not necessarily. If the generic uses selinexor Form A particles that satisfy claim 1, changing excipients may not avoid the composition claim.
Does the patent cover multiple myeloma treatment?
Yes. Claims 20 and 26 specifically recite multiple myeloma, subject to all incorporated limitations from the underlying claims.
Is a different XRPD testing method enough to avoid infringement?
Not automatically. The analysis would depend on the claim construction, the testing protocol, measurement error, batch characteristics and whether the accused material meets the claimed Form A and particle-size limitations.
References
- United States Patent and Trademark Office. (2019). U.S. Patent No. 10,519,139, solid forms of compounds and compositions comprising same.
- U.S. Food and Drug Administration. (2020). Xpovio (selinexor) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- Karyopharm Therapeutics Inc. (2020). Karyopharm announces exclusive license agreement with Antengene for selinexor in Greater China.
- Karyopharm Therapeutics Inc. (2021). Karyopharm and Menarini Group announce global commercialization agreement for Xpovio.